Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of ART-123 for the prevention of cancer treatment related symptoms in patients with postoperative stage II / III colon cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asahi Kasei Pharma Corporation

Criteria

Main Inclusion Criteria:

• Diagnosed with stage II / III colon cancer

• Deemed to have undergone curative A (Cur A) surgery

• Planning to undergo postoperative adjuvant chemotherapy

Main Exclusion Criteria:

• Have a history of hypersensitivity to any of the ingredients in thrombomodulin alfa (recombinant)

• Have any treatment history of systemic chemotherapy (including any drug in the clinical trial stage) or radiotherapy

• With active double cancer